483
Sohan L. Dua, M.DSohan L. Dua, M.D – FDA 483, Sep 21, 2023
Record Details
An FDA inspection of Sohan L. Dua, M.D. in Northridge, CA, a clinical investigator for the TRAVERSE study, revealed significant deficiencies in clinical trial conduct. Observations included the failure to promptly report serious adverse events, including a subject's death, to the study sponsor. Additionally, the firm failed to report unanticipated problems involving risk to human subjects to the Institutional Review Board and did not consistently obtain proper informed consent from subjects.
View Company Profile
ID · c871bb55-63f7-4fd2-902f-448c31cc7883
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.